Notícias e Atividades da Zealand Pharma

Zealand Pharma é uma empresa listada sob o símbolo ZEAL (DK).

Veja o organograma con seus 25 executivos principais

Biografias mais buscadas da Zealand Pharma

• Adam Steensberg, President and Chief Executive Officer
• Bernadette Connaughton, Director
• Kirsten Drejer, Vice Chairman of the Board

Recentes movimentos de executivos em Zealand Pharma

• Steven Johnson, ingressou na Companhia como Chief Development Officer  (Notícia publicada em 20 de maio de 2025).
• Utpal Singh, ingressou na Companhia como Chief Scientific Officer  (Notícia publicada em 25 de abril de 2025).

Criar um alerta
para seguir os movimentos de executivos da Zealand Pharma.

Zealand Pharma possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of Verve Therapeutics  (publicado em 17 de junho de 2025).
• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Zealand Pharma

• Zealand Pharma to participate in the Jefferies London Healthcare Conference
• Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
• Zealand Pharma Announces Financial Results for the First Nine Months of 2024
• Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
• Zealand Pharma announces that Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide
• Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
• Total number of shares and voting rights in Zealand Pharma A/S on September 30, 2024
• Zealand Pharma to participate in the 2024 Cantor Global Healthcare Conference on September 18th
• Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
• Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
• View more press releases Close

Redes sociais sobre Zealand Pharma

• Zealand Pharma na Wikipedia, Google News e Yahoo Finance
• Zealand Pharma na LinkedIn, Twitter e YouTube